ArticleNature communications2017
Cryo-EM structure of Saccharomyces cerevisiae target of rapamycin complex 2.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- Cooperative Function of Atg8- and TORC1-Mediated Activities in Yeast.Yeast (Chichester, England) · 2025Article
- Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis.Cancer gene therapy · 2025Article
- Making PI3K superfamily enzymes run faster.Advances in biological regulation · 2025Review
- The mTORC2 signaling network: targets and cross-talks.The Biochemical journal · 2024Review
- Sample Preparation for Electron Cryo-Microscopy of Macromolecular Machines.Advances in experimental medicine and biology · 2024Article
- TOR complex 2 is a master regulator of plasma membrane homeostasis.The Biochemical journal · 2022Article
- Stress- and metabolic responses of Candida albicans require Tor1 kinase N-terminal HEAT repeats.PLoS pathogens · 2022Article
- Identification of defined structural elements within TOR2 kinase required for TOR complex 2 assembly and function inMolecular biology of the cell · 2022Article
- The central moTOR of metabolism.Developmental cell · 2022Review
- RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Regulation and metabolic functions of mTORC1 and mTORC2.Physiological reviews · 2021Review
- The 3.2-Å resolution structure of human mTORC2.Science advances · 2020Article
- Ras, PI3K and mTORC2 - three's a crowd?Journal of cell science · 2020Review
- Structural Insights into TOR Signaling.Genes · 2020Review
- Review
- The Importance of TOR Kinase in Plant Development.Frontiers in plant science · 2020Review
- Chaperone-mediated ordered assembly of the SAGA and NuA4 transcription co-activator complexes in yeast.Nature communications · 2019Article
- Targeting mTOR for cancer therapy.Journal of hematology & oncology · 2019Review
- Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor GrowthCancer research · 2019Article
- Analysis of the roles of phosphatidylinositol-4,5-Molecular biology of the cell · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The target of rapamycin (TOR) kinase assembles into two distinct multiprotein complexes, conserved across eukaryote evolution. In contrast to TOR complex 1 (TORC1), TORC2 kinase activity is not inhibited by the macrolide rapamycin. Here, we present the structure of Saccharomyces cerevisiae TORC2 determined by electron cryo-microscopy. TORC2 contains six subunits assembling into a 1.4 MDa rhombohedron. Tor2 and Lst8 form the common core of both TOR complexes. Avo3/Rictor is unique to TORC2, but interacts with the same HEAT repeats of Tor2 that are engaged by Kog1/Raptor in mammalian TORC1, explaining the mutual exclusivity of these two proteins. Density, which we conclude is Avo3, occludes the FKBP12-rapamycin-binding site of Tor2's FRB domain rendering TORC2 rapamycin insensitive and recessing the kinase active site. Although mobile, Avo1/hSin1 further restricts access to the active site as its conserved-region-in-the-middle (CRIM) domain is positioned along an edge of the TORC2 active-site-cleft, consistent with a role for CRIM in substrate recruitment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.